Pr3vent has developed an AI-based platform that screens retinal images of newborns to flag potential eye abnormalities that require follow-up. The system was trained on hundreds of thousands of newborn retinal images obtained under an exclusive license and is reported to be about 97% accurate for screening. Today the company is focused on an initial screening tool to assist clinicians rather than delivering full diagnostic reads. Pr3vent has a commercialization agreement with Mednax, which gives the company access to a broad hospital customer base. The team is pursuing FDA regulatory clearance and was in the FDA pre-submission process with hopes of clearance by the end of 2020. Financially, the company recently raised a $1.5 million Series A and previously completed a $1.0 million seed round. Pr3vent is a Palo Alto, California-based healthcare IT company developing artificial intelligence and machine learning screens for ophthalmic newborn conditions. Its core product work focuses on patented algorithms and a screening service designed expressly for newborn eye screening. The company is developing an eye screening diagnostic service that applies its algorithms to detect ophthalmic conditions in newborns. Pr3vent says it will use proceeds from a recent seed funding round to accelerate development of that screening service. The company was founded by medical field veterans Jochen Kumm, PhD, and Darius M. Moshfeghi, MD. The article disclosed no operating metrics or revenue figures.

Total raised

$2M

Funding rounds

2

Latest round

Series A

Latest activity

Feb 2019